Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Vaccine
HIV-1 canarypox vaccine benefits chronically HIV-infected patients
September 14th, 2005
Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine benefited chronically HIV-infected patients. According to recent research published in the journal Vaccine, "This open single-arm study evaluated whether the administration of an HIV-recombinant canarypox vaccine (vCP1433) in highly active antiretroviral therapy (HAART)-treated patients chronically infected with HIV was safe, immunogenic, and associated with prolongation of treatment discontinuation: 48 patients received 4 monthly vCP1433 injections and stopped HAART. Immunization was safe." "HIV-p24-specific lymphoproliferative responses...
Source: Vaccine Weekly (2005-09-14)
|
